A citation-based method for searching scientific literature

Sebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, Jeremy Franklin, Martin Sebastian, Enriqueta Felip, Christian Grohé, Delvys Rodriguez-Abreu, Diana S Y Abdulla, Helge Bischoff, Christian Brandts, Enric Carcereny, Jesús Corral, Anne-Marie C Dingemans, Eva Pereira, Jana Fassunke, Rieke N Fischer, Masyar Gardizi, Lukas Heukamp, Amelia Insa, Anna Kron, Roopika Menon, Thorsten Persigehl, Martin Reck, Richard Riedel, Sacha I Rothschild, Andreas H Scheel, Matthias Scheffler, Petra Schmalz, Egbert F Smit, Meike Limburg, Mariano Provencio, Niki Karachaliou, Sabine Merkelbach-Bruse, Martin Hellmich, Lucia Nogova, Reinhard Büttner, Rafael Rosell, Jürgen Wolf. J Thorac Oncol 2019
Times Cited: 44







List of co-cited articles
440 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Julien Mazières, Solange Peters, Benoit Lepage, Alexis B Cortot, Fabrice Barlesi, Michéle Beau-Faller, Benjamin Besse, Hélène Blons, Audrey Mansuet-Lupo, Thierry Urban,[...]. J Clin Oncol 2013
410
9

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.
U Gatzemeier, G Groth, C Butts, N Van Zandwijk, F Shepherd, A Ardizzoni, C Barton, P Ghahramani, V Hirsh. Ann Oncol 2004
267
9

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
Rui Wang, Haichuan Hu, Yunjian Pan, Yuan Li, Ting Ye, Chenguang Li, Xiaoyang Luo, Lei Wang, Hang Li, Yang Zhang,[...]. J Clin Oncol 2012
343
9

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.
M G Kris, D R Camidge, G Giaccone, T Hida, B T Li, J O'Connell, I Taylor, H Zhang, M E Arcila, Z Goldberg,[...]. Ann Oncol 2015
186
9

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
Oliver Gautschi, Julie Milia, Bastien Cabarrou, Marie-Virginia Bluthgen, Benjamin Besse, Egbert F Smit, Juergen Wolf, Solange Peters, Martin Früh, Dieter Koeberle,[...]. J Thorac Oncol 2015
109
9

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
Rafal Dziadziuszko, Egbert F Smit, Urania Dafni, Juergen Wolf, Bartosz Wasąg, Wojciech Biernat, Stephen P Finn, Roswitha Kammler, Zoi Tsourti, Manuela Rabaglio,[...]. J Thorac Oncol 2019
58
9

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.
Bob T Li, Dara S Ross, Dara L Aisner, Jamie E Chaft, Meier Hsu, Severine L Kako, Mark G Kris, Marileila Varella-Garcia, Maria E Arcila. J Thorac Oncol 2016
138
9

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.
J Mazieres, C Cropet, L Montané, F Barlesi, P J Souquet, X Quantin, C Dubos-Arvis, J Otto, L Favier, V Avrillon,[...]. Ann Oncol 2020
51
9

Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.
Sebastian Michels, Andreas Hans Scheel, Matthias Scheffler, Anne Maria Schultheis, Oliver Gautschi, Franziska Aebersold, Joachim Diebold, Georg Pall, Sacha Rothschild, Lukas Bubendorf,[...]. J Thorac Oncol 2016
40
10

Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Christian Rolfo, Rossana Ruiz, Elisa Giovannetti, Ignacio Gil-Bazo, Antonio Russo, Francesco Passiglia, Marco Giallombardo, Marc Peeters, Luis Raez. Expert Opin Investig Drugs 2015
74
9

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang,[...]. Lancet Respir Med 2020
51
9

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
T Mok, D R Camidge, S M Gadgeel, R Rosell, R Dziadziuszko, D-W Kim, M Pérol, S-H I Ou, J S Ahn, A T Shaw,[...]. Ann Oncol 2020
114
9

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, Matthew D Hellmann, Mark M Awad, Justin F Gainor, Alexa B Schrock, Ryan J Hartmaier, Sally E Trabucco, Laurie Gay,[...]. Cancer Discov 2018
660
9

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.
Solange Peters, Rolf Stahel, Lukas Bubendorf, Philip Bonomi, Augusto Villegas, Dariusz M Kowalski, Christina S Baik, Dolores Isla, Javier De Castro Carpeno, Pilar Garrido,[...]. Clin Cancer Res 2019
94
9

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Keunchil Park, Eng-Huat Tan, Ken O'Byrne, Li Zhang, Michael Boyer, Tony Mok, Vera Hirsh, James Chih-Hsin Yang, Ki Hyeong Lee, Shun Lu,[...]. Lancet Oncol 2016
667
9

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
Junji Tsurutani, Hiroji Iwata, Ian Krop, Pasi A Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles Redfern, Kenji Tamura, Trisha M Wise-Draper,[...]. Cancer Discov 2020
98
9

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
F Mosele, J Remon, J Mateo, C B Westphalen, F Barlesi, M P Lolkema, N Normanno, A Scarpa, M Robson, F Meric-Bernstam,[...]. Ann Oncol 2020
200
9

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han, Maximilian J Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario García Campelo, Dong-Wan Kim,[...]. J Clin Oncol 2020
103
9

ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
Akihiko Yoshida, Takashi Kohno, Koji Tsuta, Susumu Wakai, Yasuhito Arai, Yoko Shimada, Hisao Asamura, Koh Furuta, Tatsuhiro Shibata, Hitoshi Tsuda. Am J Surg Pathol 2013
115
6

Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
Sergi Clavé, Natalia Rodon, Lara Pijuan, Olga Díaz, Marta Lorenzo, Pedro Rocha, Álvaro Taus, Remei Blanco, Joaquim Bosch-Barrera, Noemí Reguart,[...]. Clin Lung Cancer 2019
18
16

ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases.
Arne Warth, Thomas Muley, Hendrik Dienemann, Benjamin Goeppert, Albrecht Stenzinger, Philipp A Schnabel, Peter Schirmacher, Roland Penzel, Wilko Weichert. Histopathology 2014
77
6

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Martin Reck, Tony S K Mok, Makoto Nishio, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot,[...]. Lancet Respir Med 2019
400
6

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
Mark M Awad, Giulia C Leonardi, Sasha Kravets, Suzanne E Dahlberg, Alexander Drilon, Sinead A Noonan, D Ross Camidge, Sai-Hong I Ou, Daniel B Costa, Shirish M Gadgeel,[...]. Lung Cancer 2019
51
6

Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
Sinéad A Noonan, Lynne Berry, Xian Lu, Dexiang Gao, Anna E Barón, Patrick Chesnut, Jamie Sheren, Dara L Aisner, Dan Merrick, Robert C Doebele,[...]. J Thorac Oncol 2016
98
6

Somatic mutations lead to an oncogenic deletion of met in lung cancer.
Monica Kong-Beltran, Somasekar Seshagiri, Jiping Zha, Wenjing Zhu, Kaumudi Bhawe, Nerissa Mendoza, Thomas Holcomb, Kanan Pujara, Jeremy Stinson, Ling Fu,[...]. Cancer Res 2006
340
6


Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Lecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, Subba Digumarthy, Alexa B Turke, Panos Fidias, Kristin Bergethon, Alice T Shaw, Scott Gettinger, Arjola K Cosper,[...]. Sci Transl Med 2011
6

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.
Byoung Chul Cho, Radka Obermannova, Alessandra Bearz, Mark McKeage, Dong-Wang Kim, Ullas Batra, Gloria Borra, Sergey Orlov, Sang-We Kim, Sarayut L Geater,[...]. J Thorac Oncol 2019
38
7

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Scott N Gettinger, Lyudmila A Bazhenova, Corey J Langer, Ravi Salgia, Kathryn A Gold, Rafael Rosell, Alice T Shaw, Glen J Weiss, Meera Tugnait, Narayana I Narasimhan,[...]. Lancet Oncol 2016
213
6

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Paul K Paik, Alexander Drilon, Pang-Dian Fan, Helena Yu, Natasha Rekhtman, Michelle S Ginsberg, Laetitia Borsu, Nikolaus Schultz, Michael F Berger, Charles M Rudin,[...]. Cancer Discov 2015
395
6

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
Giorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, Ulrich Gatzemeier, Raghunadharao Digumarti, Mauro Zukin,[...]. J Clin Oncol 2008
6

Epidermal growth factor receptor mutations in lung cancer.
Sreenath V Sharma, Daphne W Bell, Jeffrey Settleman, Daniel A Haber. Nat Rev Cancer 2007
6

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.
S-H I Ou, P A Jänne, C H Bartlett, Y Tang, D-W Kim, G A Otterson, L Crinò, P Selaru, D P Cohen, J W Clark,[...]. Ann Oncol 2014
168
6

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
6

MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung.
Hans-Ulrich Schildhaus, Anne M Schultheis, Josef Rüschoff, Elke Binot, Sabine Merkelbach-Bruse, Jana Fassunke, Wolfgang Schulte, Yon-Dschun Ko, Andreas Schlesinger, Marc Bos,[...]. Clin Cancer Res 2015
114
6

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
A Kron, C Alidousty, M Scheffler, S Merkelbach-Bruse, D Seidel, R Riedel, M A Ihle, S Michels, L Nogova, J Fassunke,[...]. Ann Oncol 2018
76
6

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.
James P Solomon, Irina Linkov, Andrea Rosado, Kerry Mullaney, Ezra Y Rosen, Denise Frosina, Achim A Jungbluth, Ahmet Zehir, Ryma Benayed, Alexander Drilon,[...]. Mod Pathol 2020
183
6

Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.
Dickran Kazandjian, Gideon M Blumenthal, Lola Luo, Kun He, Ingrid Fran, Steven Lemery, Richard Pazdur. Oncologist 2016
50
6

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Masahiro Fukuoka, Yi-Long Wu, Sumitra Thongprasert, Patrapim Sunpaweravong, Swan-Swan Leong, Virote Sriuranpong, Tsu-Yi Chao, Kazuhiko Nakagawa, Da-Tong Chu, Nagahiro Saijo,[...]. J Clin Oncol 2011
6

Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer.
Liang Zeng, Yizhi Li, Lili Xiao, Yi Xiong, Li Liu, Wenjuan Jiang, Jianfu Heng, Jingjing Qu, Nong Yang, Yongchang Zhang. Onco Targets Ther 2018
11
27

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Robert C Doebele, Amanda B Pilling, Dara L Aisner, Tatiana G Kutateladze, Anh T Le, Andrew J Weickhardt, Kimi L Kondo, Derek J Linderman, Lynn E Heasley, Wilbur A Franklin,[...]. Clin Cancer Res 2012
795
6

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Alexander Drilon, Ramamoorthy Nagasubramanian, James F Blake, Nora Ku, Brian B Tuch, Kevin Ebata, Steve Smith, Veronique Lauriault, Gabrielle R Kolakowski, Barbara J Brandhuber,[...]. Cancer Discov 2017
216
6

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Deepa Rangachari, Paul A VanderLaan, Meghan Shea, Xiuning Le, Mark S Huberman, Susumu S Kobayashi, Daniel B Costa. J Thorac Oncol 2017
94
6

Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer.
Jessica J Lin, Emily Chin, Beow Y Yeap, Lorin A Ferris, Vashine Kamesan, Inga T Lennes, Lecia V Sequist, Rebecca S Heist, Mari Mino-Kenudson, Justin F Gainor,[...]. J Thorac Oncol 2019
50
6

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).
David R Spigel, Craig Reynolds, David Waterhouse, Edward B Garon, Jason Chandler, Sunil Babu, Paul Thurmes, Alexander Spira, Robert Jotte, Jin Zhu,[...]. J Thorac Oncol 2018
126
6

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Sen Zhang, Rana Anjum, Rachel Squillace, Sara Nadworny, Tianjun Zhou, Jeff Keats, Yaoyu Ning, Scott D Wardwell, David Miller, Youngchul Song,[...]. Clin Cancer Res 2016
185
6

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.
Monika A Davare, Anna Saborowski, Christopher A Eide, Cristina Tognon, Rebecca L Smith, Johannes Elferich, Anupriya Agarwal, Jeffrey W Tyner, Ujwal P Shinde, Scott W Lowe,[...]. Proc Natl Acad Sci U S A 2013
83
6

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.
Alexander Drilon, Jessica J Lin, Thomas Filleron, Ai Ni, Julie Milia, Isabella Bergagnini, Vaios Hatzoglou, Vamsidhar Velcheti, Michael Offin, Bob Li,[...]. J Thorac Oncol 2018
68
6

Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21).
Alain Charest, Keara Lane, Kevin McMahon, Julie Park, Elizabeth Preisinger, Helen Conroy, David Housman. Genes Chromosomes Cancer 2003
142
6

Characteristics of Patients With ROS1+ Cancers: Results From the First Patient-Designed, Global, Pan-Cancer ROS1 Data Repository.
Divya A Parikh, Guneet Walia, Janet Freeman-Daily, Merel Hennink, Tori Tomalia, Lysa Buonanno, Lisa Goldman, Bonnie Addario, Manali I Patel. JCO Oncol Pract 2020
7
42


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.